progressive multifocal leukoencephalopathy (PML)suspension of market authorizationSummary Efalizumab is a humanized monoclonal antibody (mAb) to lymphocyte-function-associated antigen (LFA-1). mAbs to LFA-1 inhibit LFA-1 interaction with intracellular adhesion molecule (ICAM), leading to the inhibition of...
Efalizumab (78 ng/mL-5 mg/mL)诱导白细胞增多,下调外周血T细胞LFA-1的表达。 Efalizumab (78 ng/mL-5 mg/mL)下调板结合、抗cd3刺激的PBMC增殖。 MCE尚未独立证实这些方法的准确性。仅供参考。 体内研究 Efalizumab显示的副作用包括细菌性败血症、病毒性脑膜炎、侵袭性真菌病和进行性多灶性脑白质病(PML), P...
体内实验:依法珠单抗的副作用包括细菌性败血症、病毒性脑膜炎、侵袭性真菌病和进行性多灶性白质脑病 (PML),这是一种由潜伏 JC 病毒感染再激活引起的脑部感染[2]. 体外:依法利珠单抗(78 ng/mL-5 mg/mL)诱导白细胞增多,并下调外周血中 T 细胞上的 LFA-1 表达[3]。依法利珠单抗(78 ng/mL-5 mg/mL)下调...
Efalizumab在使用过程中可能导致包括细菌性败血症、病毒性脑膜炎、侵袭性真菌病以及由潜伏的JC病毒感染重新激活引起的进行性多灶性白质脑病(PML)等副作用[2]。 别名依法利珠单抗, Hu1124, HU 1124 化学信息 分子量146.14 kDa CAS No.214745-43-4 储存&溶解度 ...
不良反应 RAPTIVA治疗期间观察到的最严重的不良反应有严重感染包括PML、恶性肿瘤、血小板减少、溶血性贫血、关节炎事件、银屑病恶化和变异以及神经系统事件 免疫原性 在临床试验中,在 6.3% (67/1063)的患者中检测到抗抗体。©2022 Baidu |由 百度智能云 提供计算服务 | 使用百度前必读 | 文库协议 | 网站地图 |...
Efalizumab is an anti-CD11a antibody immunosuppressant drug. PML is a rapidly progressive infection of the central nervous system caused by the John Cunningham (JC) virus that leads to death or severe disability. It is currently not possible to identify patients at increased risk for PML before ...
(FDA MedWatch definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * requires intervention to prevent permanent impairment or damage A man [ age not stated ] developed progressive multifocal leukoencephalopathy (PML) after receiving ...
had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML)...
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event ... ES Molloy,LH Calabrese - 《Nature Reviews Rheumatology》 被...
Efalizumab (78 ng/mL-5 mg/mL)下调板结合、抗cd3刺激的PBMC增殖。 MCE尚未独立证实这些方法的准确性。仅供参考。 体内研究 Efalizumab显示的副作用包括细菌性败血症、病毒性脑膜炎、侵袭性真菌病和进行性多灶性脑白质病(PML), PML是一种由潜伏JC病毒感染再激活引起的脑感染。